Development and Validation of Novel Spectro- Chemometric, Chemometric and TLC-Densitometric Methods for Simultaneous Determination of Timolol and Travoprost in their Bulk Powders and Pharmaceutical Formulation

Timolol (TIM) (Figure 1a) is (S)-1-(tert-butylamino)-3-[(4morpholin-4-yl-1,2,5-thiadiazole-3-yl) oxy] propan-2-ol. Timolol maleate is nonselective β-adrenergic receptors in the heart and decreases renin activity, all of which may play a role in reducing systolic and diastolic blood pressure. TIM is indicated for treatment of mild to moderate hypertension, reduction of mortality after myocardial infarction and migraine prophylaxis [1]. Travoprost (TRA) (Figure 1b) is chemically [1R-[1ᾳ(Z),2β(1E,3R),3ᾳ,5ᾳ]]7-[3,5-Dihydroxy-2-[3-hydroxy-4[3-(trifluoromethyl) phenoxy]1-butenyl]cyclopentyl]-5-heptenoic acid-1-methyl-ethyleste. Travoprost is used in the treatment of glaucoma [1]. Both drugs are still used as a binary mixture in some pharmaceutical preparations for treatment of reduction of elevated intraocular pressure with open-angle glaucoma. Several analytical procedures are available for the analysis of the cited drugs in their bulk forms, multi-component mixtures, dosage forms or biological mixtures. These procedures are UV-Vis spectrophotometric [1-8], HPLC [9-18], HPTLC [1921] and Chemometric [22,23] assay methods are reported in the literature for the estimation of TIM and TRA individually and in combination with other dugs. For the time being only few reports were found on the direct determination of binary mixture of TIM and TRA through HPLC and direct UV methods [1,15-18]. For this reason, this study describes for the first time the simultaneous ISSN: 2641-2020 DOI: 10.33552/APPR.2019.02.000527